Skip to main content
SpringerLink
Log in

Metabolisches Profiling und Prostatakarzinomrisiko: Chance für „liquid biopsies“?

Ergebnisse der prospektiven, fallkontrollierten EPIC-Studie

Metabolic profiling and prostate cancer risk: opportunity for liquid biopsies?

Results from the prospective, case–controlled EPIC study

  • Journal Club
  • Published:
Der Urologe Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Riboli E, Hunt KJ, Slimani N, Ferrari P, Norat T, Fahey M, Overvad K (2002) European prospective investigation into cancer and nutrition (EPIC): study populations and data collection. Public Health Nutr 5(6b):1113–1124

    Article  CAS  Google Scholar 

  2. Taniguchi M, Okazaki T (2014) The role of sphingomyelin and sphingomyelin synthases in cell death, proliferation and migration—from cell and animal models to human disorders. Biochim Biophys Acta 1841(5):692–703

    Article  CAS  Google Scholar 

  3. Kühn T, Floegel A, Sookthai D, Johnson T, Rolle-Kampczyk U, Otto W, Kaaks R et al (2016) Higher plasma levels of lysophosphatidylcholine 18: 0 are related to a lower risk of common cancers in a prospective metabolomics study. BMC Med 14(1):13

    Article  Google Scholar 

  4. Shu X, Xiang YB, Rothman N, Yu D, Li HL, Yang G, Jia W (2018) Prospective study of blood metabolites associated with colorectal cancer risk. Int J Cancer 143(3):527–534

    Article  CAS  Google Scholar 

  5. Fages A, Duarte-Salles T, Stepien M, Ferrari P, Fedirko V, Pontoizeau C, Clavel-Chapelon F (2015) Metabolomic profiles of hepatocellular carcinoma in a European prospective cohort. BMC Med 13(1):242

    Article  Google Scholar 

  6. Boyd LK, Mao X, Lu YJ (2012) The complexity of prostate cancer: genomic alterations and heterogeneity. Nat Rev Urol 9(11):652

    Article  Google Scholar 

  7. Adams CD et al (2019) Circulating metabolic biomarkers of screen-detected prostate cancer in the ProtecT study. Cancer Epidemiol Biomarkers Prev 1(28):208–216

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik und Poliklinik für Urologie und Kinderurologie, Julius-Maximilians-Universität Würzburg, Oberdürrbacher Str. 6, 97080, Würzburg, Deutschland

    C. Kalogirou & M. Krebs

  2. Comprehensive Cancer Center Mainfranken, Julius-Maximilians-Universität Würzburg, Würzburg, Deutschland

    M. Krebs

Authors
  1. C. Kalogirou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Krebs
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C. Kalogirou.

Ethics declarations

Interessenkonflikt

C. Kalogirou und M. Krebs geben an, dass kein Interessenkonflikt besteht.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kalogirou, C., Krebs, M. Metabolisches Profiling und Prostatakarzinomrisiko: Chance für „liquid biopsies“?. Urologe 59, 839–840 (2020). https://doi.org/10.1007/s00120-020-01225-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00120-020-01225-6

Search

Navigation